Extending the role of peritoneal dialysis: Can we win hearts and minds?

Nephrology Dialysis Transplantation

Volumn 29, Issue 9, 2014, Pages 1648-1654

  Davies, Simon ^a,b   Lally, Frank ^a   Satchithananda, Duwarakan ^a   Kadam, Umesh ^a   Roffe, Christine ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Excitotoxicity; Glutamate; Heart failure; Stroke; Ultrafiltration

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DIURETIC AGENT; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN;

ARTICLE; BIODEGRADATION; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN FUNCTION; BRAIN INFARCTION SIZE; CARDIORENAL SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; CORONARY ARTERY BLOOD FLOW; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DIURETIC THERAPY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEART FAILURE; HOME CARE; HOSPITALIZATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FAILURE; MOLECULAR WEIGHT; MORBIDITY; NERVE CELL NECROSIS; NERVE CELL STIMULATION; NEUROPROTECTION; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SOLUTE; SURVIVAL RATE; THEORETICAL STUDY; ULTRAFILTRATION; AMINO ACID BRAIN LEVEL; AMINO ACID TRANSPORT; BRAIN INFARCTION; BRAIN TISSUE; DIURETIC RESISTANT HEART FAILURE; EXCITOTOXICITY; HEMODIAFILTRATION; OUTCOME ASSESSMENT; THERAPY EFFECT; ADVERSE EFFECTS; ANIMAL; BRAIN; FEMALE; MALE; METABOLISM; PATIENT SELECTION; RENAL INSUFFICIENCY; STROKE;

ANIMALS; BRAIN; FEMALE; GLUTAMIC ACID; HEART FAILURE; HUMANS; MALE; NEUROTOXINS; PATIENT SELECTION; PERITONEAL DIALYSIS; RENAL INSUFFICIENCY; STROKE; ULTRAFILTRATION;

EID: 84907393758     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu001     Document Type: Article

References (52)

1. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340
2. Burke JF, Lisabeth LD, Brown DL et al. Determining stroke's rank as a cause of death using multicause mortality data. Stroke 2012; 43: 2207-2211
3. Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis 2004; 13: 171-177x
4. Neumann T, Biermann J, Erbel R et al. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 2009; 106: 269-275
5. Hall MJ, Levant S, DeFrances CJ. Hospitalization for Congestive Heart Failure: United States, 2000-2010. NCHS Data Brief No 108. Hyattsville, MD: National Center for Health Statistics, 2012.
6. Sharpe N, Murdoch DR, McMurray J. Epidemiological perspectives on heart failure: common, costly, disabling, deadly. In: Sharpe N. (ed.). Heart Failure Management. London: Martin Dunitz, 2000
7. Christensen K, Doblhammer G, Rau R et al. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196-1208
8. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130 (4S Suppl): 1007S-1015S
9. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int 2007; 50: 941-953
10. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87: 779-789
11. Xing C, Arai K, Lo EH et al. Pathophysiologic cascades in ischemic stroke. Int J Stroke 2012; 7: 378-385
12. Castellanos M, Sobrino T, Pedraza S et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008; 71: 1862-1868
13. O'Kane RL, Martinez-Lopez I, DeJoseph MR et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999; 274: 31891-5
14. Teichberg VI, Cohen-Kashi-Malina K, Cooper I et al. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 2009; 158: 301-308
15. Campos F, Sobrino T, Ramos-Cabrer P et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011; 31: 1378-1386
16. Heiss WD. The ischemic penumbra: how does tissue injury evolve? Ann N Y Acad Sci 2012; 1268: 26-34
17. Minnerup J, Sutherland BA, Buchan AM et al. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci 2012; 13: 11753-11772
18. Rogachev B, Tsesis S, Gruenbaum BF et al. The effects of peritoneal dialysis on blood glutamate levels: implementation for neuroprotection. J Neurosurg Anesthesiol 2013; 25: 262-266
19. Selby NM, McIntyre CW. Peritoneal dialysis is not associated with myocardial stunning. Perit Dial Int 2011; 31: 27-33
20. Pletinck A, Verbeke F, Van Bortel L et al. Acute central haemodynamic effects induced by intraperitoneal glucose instillation. Nephrol Dial Transplant 2008; 23: 4029-4035
21. Verbeke F, Van Biesen W, Pletinck A et al. Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int 2008; 28: 142-148
22. del Carmen Godino M, Romera VG, Sánchez-Tomero JA et al. Amelioration of ischemic brain damage by peritoneal dialysis. J Clin Invest 2013; 123: 4359-4363
23. Xu SY, Pan SY. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci Monit Basic Res 2013; 19: 37-45
24. Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev 2004; 1: CD003986
25. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 1: 383-386
26. Stroke Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). 2008. http://publications.nice.org.uk/stroke-cg68
27. Wańkowicz Z, Próchnicka A, Olszowska A et al. Extracorporeal versus peritoneal ultrafiltration in diuretic-resistant congestive heart failure - a review. Med Sci Monit 2011; 17: RA271-RA281
28. Taheri S, Mortazavi M, Pourmoghadas A et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012; 23: 507-512
29. Lambie M, Chess J, Donovan KL et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24: 2071-2080
30. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intens Care Med 2008; 34: 957-962
31. Próchnicka A, Krzesiński P, Hałas K et al. Diuretic-resistant congestive heart failure treated successfully with peritoneal ultrafiltration. Kardiol Pol 2013; 71: 393-395
32. Ishimoto Y, Mise N, Tanaka M et al. Peritoneal dialysis combined with extracorporeal ultrafiltration in refractory heart failure: a case report. Perit Dial Int 2013; 33: 582-583
33. Ruhi Ç, Koçak H, Yavuz A et al. Use of peritoneal ultrafiltration in the elderly refractory congestive heart failure patients. Int Urol Nephrol 2012; 44: 963-969
34. Brown EA, Johansson L. Dialysis options for end-stage renal disease in older people. Nephron Clin Pract 2011; 119 (Suppl 1): c10-c13
35. Pego C, Rodrigues A, Ronco C. Role of peritoneal dialysis as a chronic renal replacement therapy in cardiorenal patients. Contrib Nephrol 2012; 178: 182-188
36. Sav T, Inanc MT, Dogan A et al. Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients. Nephrology (Carlton) 2010; 15: 307-312
37. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59: 1128-1133
38. Li PK, Chow KM, Wong TY et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-112
39. Davies S, Carlsson O, Simonsen O et al. The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant 2009; 24: 1609-1617
40. Nakayama M, Nakano H, Nakayama M. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 2010; 55: 49-54
41. Sotirakopoulos NG, Kalogiannidou IM, Tersi ME et al. Peritoneal dialysis for patients suffering from severe heart failure. Clin Nephrol 2011; 76: 124-129
42. Cnossen TT, Kooman JP, Konings CJ et al. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 2010; 30: 146-152
43. Cnossen TT, Kooman JP, Krepel HP et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant 2012; 27: 2794-2799
44. Núñez J, González M, Miñana G et al. Continuous ambulatory peritoneal dialysis and clinical outcomes in patients with refractory congestive heart failure. Rev Esp Cardiol (Engl Ed) 2012; 65: 986-995
45. Núñez J, González M, Miñana G et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 2012; 14: 540-548
46. Kunin M, Arad M, Dinour D et al. Peritoneal dialysis in patients with refractory congestive heart failure: potential prognostic factors. Blood Purif 2013; 35: 285-294
47. Rizkallah J, Sood MM, Reslerova M et al. Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series. Clin Nephrol 2013; 80: 334-341
48. Courivaud C, Kazory A, Crépin T et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int 2013. PubMed PMID: 23994842
49. Bertoli SV, Musetti C, Ciurlino D et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int 2013. PubMed PMID: 24179103
50. Bart BA, Goldsmith SR, Lee KL et al. For the Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304
51. Sens F, Schott-Pethelaz AM, Labeeuw M et al. REIN Registry. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. Kidney Int 2011; 80: 970-977
52. Vonesh EF, Snyder JJ, Foley RN et al. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl 2006; 103: S3-11